HR and breast carcinoma: More recently, cyclin-dependent kinase (CDK)4/6 inhibitors have emerged as a cornerstone in breast cancer management and are recommended as adjuvant treatment for patients with HR+, HER2− early breast cancer who are considered at high risk for disease recurrence.